Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Change in Account Payables (2017 - 2025)

Historic Change in Account Payables for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to $962000.0.

  • Puma Biotechnology's Change in Account Payables rose 11605.74% to $962000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 million, marking a year-over-year decrease of 14587.42%. This contributed to the annual value of -$1.4 million for FY2024, which is 40734.97% down from last year.
  • Per Puma Biotechnology's latest filing, its Change in Account Payables stood at $962000.0 for Q3 2025, which was up 11605.74% from -$602000.0 recorded in Q2 2025.
  • In the past 5 years, Puma Biotechnology's Change in Account Payables ranged from a high of $8.9 million in Q3 2021 and a low of -$8.9 million during Q4 2021
  • Moreover, its 5-year median value for Change in Account Payables was $512000.0 (2021), whereas its average is -$299473.7.
  • Data for Puma Biotechnology's Change in Account Payables shows a peak YoY increase of 106701.71% (in 2021) and a maximum YoY decrease of 186305.31% (in 2021) over the last 5 years.
  • Puma Biotechnology's Change in Account Payables (Quarter) stood at -$8.9 million in 2021, then increased by 4.35% to -$8.5 million in 2022, then surged by 121.54% to $1.8 million in 2023, then plummeted by 209.41% to -$2.0 million in 2024, then soared by 148.1% to $962000.0 in 2025.
  • Its Change in Account Payables stands at $962000.0 for Q3 2025, versus -$602000.0 for Q2 2025 and $517000.0 for Q1 2025.